Statins: we need an independent reviewBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4992 (Published 15 September 2016) Cite this as: BMJ 2016;354:i4992
Documents relating to a complaint about The BMJ made to COPE - updated in November 2016
- Fiona Godlee, editor in chief
- The BMJ
Statins are back in the news. A review published in the Lancet last week, covered in our news story (doi:10.1136/bmj.i4893), presents what its authors clearly consider to be a definitive account of the evidence on statins that should, they say, bring an end to a dangerous debate.
Not everyone agrees. Though the benefits of statins for secondary prevention or in people at high risk of cardiovascular disease are undisputed, proposals to offer them to large numbers of people at lower risk remain controversial, much to the frustration of the statin trialists who authored the Lancet review. …